Please click on the timeline below to review the key developments in our company and product timeline.
Swedish Biomimetics 3000® AB founded by Lars-Uno Larsson.
The company strategic focus was exploring Biomimetic concepts as a Venture Philanthropic Organisation (VPO)1.
1BIOCENTURY MAY 30TH, 2005, Vol 13, No 24
UK subsidiary Swedish Biomimetics 3000® Limited founded by Lars-Uno Larsson.
Worldwide licensing agreement executed for µLOT® with Andrew Prewer and The University of East Anglia.
Worldwide licensing agreement executed for µMIST® with University of Leeds.
The strategic focus of the company transferred to V2IO® (virtual, venture, intersectional organisation).
EPSRC funding obtained with University of Leeds for translational research into defensive spray of the Bombardier Beetle (µMIST®).
The µLOT® development was based at the John Innes Centre in Norwich. The initial prototype for µLOT® was produced, followed by the modular prototype which was used to complete a continuous flow peptide coupling and washing experiments.
Core patents for µLOT® and µMIST® were filed.
µMIST® development continues at University of Leeds with the addition of a research facility at Birmingham Science Park Aston.
µMIST® awarded a Carbon Connection Grant for the µMIST® fuel injector development program.
µLOT® Proof-of-Principle synthesis completed.
µMIST® Respiratory Drug Delivery development initiated with support from i4i.
Swedish Biomimetics 3000® received the THES Award with The University of Leeds on the µMist® Platform Technology for “Outstanding Contribution to Innovation & Technology”.
Collaborative Research and Development office in Lund established.
UK Operations consolidated to Oxford Science Park.
Reaction enhancement for the µLOT® system utilising microwave energisation was designed and implemented.
The µLOT® Proof-of-Concept was established by microwave of an Integrilin analogue (a cyclic heptapeptide).
Core patents for µLOT® and µMIST® granted.
µLOT® nominated for The Times Higher Education 2013 “Outstanding Contribution to Innovation & Technology Award” in London.
Swedish Biomimetics 3000® Ltd received a TSB grant for a project to investigate applications of the µLOT®system in biopharmaceutical manufacturing.
µMist®Diesel Fuel Injector Development begins with Lund University and Swedish Energy Agency Support.
The µLOT® external development team was formed and expanded to include engagement with industrial partners, service providers, peptide experts, regulatory and commercial advisors.
Agreement signed with Red Glead Discovery AB, a leading CRO with expertise in peptide synthesis and the peptide market.
Work on defining the Commercial Launch Facility, performed with a modular construction company.
Due to the prevailing positive market and regulatory environment, the decision was made to accelerate development within Swedish Biomimetics 3000® on the µLOT® development.
µMIST® development continued in the consumer and automotive sectors.